ATP23

Across TCGA pan-cancer cohorts, ATP23 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP23 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP23 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATP23 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where ATP23 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	1.000	0.907	.021	4	view →
GBM	DFS	Median	All	0.400	0.242	.036	2	view →
LUAD	DFS	Median	II,III,IV	1.000	0.726	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP23–CCRCC (OS)

Open the CCRCC breakdown →